AfricaRegulatory
African Pharmaceutical Regulatory Intelligence
INFLIXIMAB
8 registrations across 5 African markets— 6 active
Markets with INFLIXIMAB
Recent registrations
| Brand / Product | Market | Holder | Status | Expires |
|---|---|---|---|---|
| Remicads 100mg Powder for Concentrate for Solution (Infliximab) | 🇬🇭Ghana | — | active | May 2031 |
| Remicads 100mg Powder for Concentrate for Solution (Infliximab) | 🇬🇭Ghana | — | active | May 2031 |
| Remicade** Powder for concentrate for solution for infusion | 🇳🇬Nigeria | J & J Company West Africa Limited | active | Jun 2028 |
| REMSIMA Pdre p.prep.injectable / 100 mg | 🇹🇳Tunisia | HIKMA Pharmaceuticals | expired | Jul 2017 |
| REMICADE Pdre p.prep.injectable / 100 mg | 🇹🇳Tunisia | JANSSEN BIOLOGICS B.V | expired | Aug 2003 |
| REMIFLIX | 🇿🇦South Africa | Cipla Medpro (Pty) Ltd | active | Jan 1900 |
| REVELLEX 100 mg | 🇿🇦South Africa | Janssen Pharmaceutica (Pty) Ltd | active | Jan 1900 |
| REMICADE POUDRE POUR PERFUSION | 🇲🇦Morocco | — | active | — |
INFLIXIMAB in Africa — Regulatory Overview
INFLIXIMAB is registered across 5 African markets with 8 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Ghana, Tunisia, South Africa, Morocco and 1 more. AfricaRegulatory refreshes this data daily from official government sources.
Of the 8 registrations, 6 (75%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.